全球癌症免疫治疗市场：2025-2030 年预测

癌症免疫治疗市场预计将从 2025 年的 1,678.62 亿美元成长到 2030 年的 3,412.73 亿美元，复合年增长率为 15.25%。

由于癌症发病率的上升以及利用人体免疫系统对抗癌细胞的治疗方法的进步，癌症免疫疗法市场正在经历强劲增长。免疫疗法利用人体自然防御机制来辨识和清除癌症，提供一种比传统疗法毒性更低的标靶治疗方案。大量的研发投入、先进疗法的日益普及以及日益提升的癌症认知度，为该市场的发展提供了支撑。然而，高昂的治疗费用和冗长的监管核准流程对市场扩张构成了挑战。儘管面临这些挑战，但预计该市场仍将继续成长，尤其是在医疗基础设施完善的地区以及癌症发生率不断上升的新兴国家。

主要成长要素

投资先进免疫疗法

癌症免疫疗法市场得到了大型製药企业和研究机构的大力投资。这些投资专注于开发标靶免疫疗法，例如查核点抑制剂和CAR-T细胞疗法，以增强疗效并最大程度地减少副作用。行业领导者之间的合作正在加速新药开发，以解决癌症治疗中尚未满足的需求并改善患者疗效，从而推动市场成长。

肺癌发生率上升

由于吸烟和环境暴露等因素导致肺癌发生率不断上升，对市场成长贡献巨大。由于肺癌在世界范围内发病率高，它在免疫疗法市场中占据了很大份额。新兴经济体高昂的医疗支出以及有效治疗方法的研发推动了免疫疗法的普及，预计将进一步推动对免疫疗法的需求，尤其是针对肺癌的特异性治疗方法。

目录

第一章执行摘要

第二章市场概述

• 市场概览
• 市场定义
• 调查范围
• 市场区隔

第三章 经营状况

• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析
• 产业价值链分析
• 政策法规
• 策略建议

第四章 技术展望

第五章全球癌症免疫治疗市场（按类型）

• 介绍
• 单株抗体（MAB）
• 查核点抑制剂
• 细胞激素
• 癌症疫苗
• 过继细胞移植

第六章全球癌症免疫治疗市场（按应用）

• 介绍
• 黑色素瘤
• 肺癌
• 白血病
• 膀胱癌
• 乳癌
• 大肠直肠癌
• 其他的

第七章全球癌症免疫治疗市场（按最终用户）

• 介绍
• 医院和诊所
• 癌症研究中心

第八章全球癌症免疫治疗市场（按地区）

• 介绍
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 义大利
  • 英国
  • 其他的
• 中东和非洲
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 其他的

第九章：竞争格局及分析

• 主要企业和策略分析
• 市场占有率分析
• 合併、收购、协议和合作
• 竞争对手仪表板

第十章：公司简介

• Servier
• Sanofi
• Xencor
• Pfizer Inc.
• Cellectis SA
• CytomX Therapeutics, Inc.
• Bristol-Myers Squibb Company
• Nektar
• Eisai Co., Ltd.
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd.

第十一章 附录

• 货币
• 先决条件
• 基准年和预测年时间表
• 相关人员的主要利益
• 调查方法
• 简称

The global cancer immunotherapy market is expected to grow from USD 167.862 billion in 2025 to USD 341.273 billion in 2030, at a CAGR of 15.25%.

The global cancer immunotherapy market is experiencing robust growth, driven by the increasing prevalence of cancer and advancements in therapies that harness the body's immune system to combat cancer cells. Immunotherapy leverages natural defense mechanisms to identify and eliminate cancer, offering targeted treatment options with reduced toxicity compared to traditional methods. The market is propelled by significant investments in research and development, growing adoption of advanced therapies, and rising cancer awareness. However, high treatment costs and lengthy regulatory approval processes pose challenges to market expansion. Despite these hurdles, the market is poised for continued growth, particularly in regions with strong healthcare infrastructure and emerging economies with rising cancer incidences.

Key Growth Drivers

Investments in Advanced Immunotherapies

The cancer immunotherapy market is bolstered by substantial investments from major pharmaceutical companies and research organizations. These investments focus on developing targeted immunotherapies, such as checkpoint inhibitors and CAR-T cell therapies, which enhance efficacy and minimize side effects. Collaborative efforts among industry leaders are accelerating the development of novel drugs, driving market growth by addressing unmet needs in cancer treatment and improving patient outcomes.

Rising Incidence of Lung Cancer

The increasing prevalence of lung cancer, driven by factors such as smoking and environmental exposures, significantly contributes to market growth. Lung cancer holds a substantial share of the immunotherapy market due to its high global incidence. The adoption of immunotherapies, supported by high healthcare expenditure in developed economies and ongoing research into effective treatments, is expected to further propel demand, particularly for lung cancer-specific therapies.

Market Segmentation

By Application

The cancer immunotherapy market is segmented into skin cancer, lung cancer, leukemia, bladder cancer, and others. Lung cancer dominates due to its high prevalence and the growing adoption of immunotherapies in regions with strong healthcare systems. Bladder cancer and leukemia also hold significant shares, driven by increased research and development investments targeting these cancer types, which require specialized immunotherapeutic approaches to improve patient outcomes.

By Geography

The market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. North America is expected to maintain a significant market share, driven by early adoption of innovative therapies, a high prevalence of cancer, and substantial R&D investments. The presence of key market players and a robust regulatory framework, including FDA approvals for immunotherapy drugs, further supports growth. Asia-Pacific is projected to experience rapid growth, fueled by an increasing cancer patient pool, rising awareness, and technological advancements in countries like India and China, where clinical trials for therapies like CAR-T are expanding.

Competitive Landscape

Key players, including Bristol-Myers Squibb Company, Eisai Co., Ltd., Nektar, and Servier, are driving innovation through collaborative research and development of advanced immunotherapies. These companies focus on novel drug combinations and targeted therapies to enhance treatment efficacy and expand market reach.

The cancer immunotherapy market is set for significant growth, propelled by rising cancer incidences, particularly lung cancer, and substantial investments in advanced therapies. North America leads due to its strong healthcare infrastructure, while Asia-Pacific's rapid expansion reflects growing patient needs and clinical advancements. Despite challenges like high costs and regulatory delays, the market's trajectory remains positive, driven by ongoing innovation and the critical role of immunotherapy in transforming cancer treatment.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2020 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation:

The global cancer immunotherapy market has been analyzed through the following segments:

By Type

• Monoclonal antibodies (MABs)
• Checkpoint Inhibitors
• Cytokines
• Cancer vaccines
• Adoptive Cell Transfer

By Application

• Melanoma
• Lung Cancer
• Leukemias
• Bladder Cancer
• Breast Cancer
• Colorectal Cancer
• Others

By End User

• Hospitals and Clinics
• Cancer Research Centers
• Canada

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• Italy
• United Kingdom
• Others
• Middle East and Africa
• Israel
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL CANCER IMMUNOTHERAPY MARKET BY TYPE

• 5.1. Introduction
• 5.2. Monoclonal antibodies (MABs)
• 5.3. Checkpoint Inhibitors
• 5.4. Cytokines
• 5.5. Cancer vaccines
• 5.6. Adoptive Cell Transfer

6. GLOBAL CANCER IMMUNOTHERAPY MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Melanoma
• 6.3. Lung Cancer
• 6.4. Leukemias
• 6.5. Bladder Cancer
• 6.6. Breast Cancer
• 6.7. Colorectal Cancer
• 6.8. Others

7. GLOBAL CANCER IMMUNOTHERAPY MARKET BY END USER

• 7.1. Introduction
• 7.2. Hospitals and Clinics
• 7.3. Cancer Research Centers

8. GLOBAL CANCER IMMUNOTHERAPY MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. Italy
  • 8.4.4. United Kingdom
  • 8.4.5. Others
• 8.5. Middle East & Africa
  • 8.5.1. Israel
  • 8.5.2. Saudi Arabia
  • 8.5.3. UAE
  • 8.5.4. Others
• 8.6. Asia Pacific
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. Australia
  • 8.6.5. South Korea
  • 8.6.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Servier
• 10.2. Sanofi
• 10.3. Xencor
• 10.4. Pfizer Inc.
• 10.5. Cellectis SA
• 10.6. CytomX Therapeutics, Inc.
• 10.7. Bristol-Myers Squibb Company
• 10.8. Nektar
• 10.9. Eisai Co., Ltd.
• 10.10. Merck & Co., Inc.
• 10.11. F. Hoffmann-La Roche Ltd.

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations